P043 Response Loss When Transferring Patients With Inflammatory Bowel Disease From the Original Drug Infliximab to Its Biosimilar

Autor:	Dmitriy Kulakov, A V Kagramanova, A I Parfenov, T.V. Shkurko, Oleg Knyazev, A A Lishchinskaya, Mariya Zvyaglova
Rok vydání:	2019
Předmět:	Drug medicine.medical_specialty Hepatology business.industry media_common.quotation_subject Gastroenterology Biosimilar medicine.disease Inflammatory bowel disease Infliximab Internal medicine medicine business media_common medicine.drug
Zdroj:	American Journal of Gastroenterology. 114:S11-S11
ISSN:	1572-0241 0002-9270
DOI:	10.14309/01.ajg.0000613140.80198.8a
Databáze:	OpenAIRE
Externí odkaz:	https://explore.openaire.eu/search/publication?articleId=doi_________::d77453482874443c8c7d00481fb88bdd https://doi.org/10.14309/01.ajg.0000613140.80198.8a Zobrazit plný text záznamu